New Immunotherapy-Chemo cocktail aims to boost cervical cancer survival
NCT ID NCT07244965
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding the immunotherapy drug ivonescimab to chemotherapy before standard chemoradiation can improve outcomes for women with high-risk, locally advanced cervical cancer. About 42 participants will receive two cycles of the combination, then proceed to standard chemoradiation. The study measures how long the cancer stays under control and how well the tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ivonescimab (an immunotherapy drug) combined with paclitaxel and cisplatin (chemotherapy)
- What this could lead to
- If it works, this could offer a new treatment approach to shrink tumors before standard chemoradiation, potentially improving survival for women with advanced cervical cancer.
- What could go wrong
- This is a small, early-phase trial with only 42 participants and no comparison group. The combination may cause significant side effects, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CERVICAL CANCERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Women's Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.